Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$2.05 USD
+0.01 (0.49%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.03 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMMX 2.05 +0.01(0.49%)
Will IMMX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMMX
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
IMMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
Other News for IMMX
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma Shareholders Back Growth and Governance Changes
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024